<DOC>
	<DOCNO>NCT01726322</DOCNO>
	<brief_summary>Primary Objective : To determine whether pre-treatment level anti-mullerian hormone predict ovarian follicular reserve post adjuvant neoadjuvant chemotherapy breast cancer chemotherapy induce amenorrhea ( CIA ) . Secondary Objective - To evaluate comparative ovarian toxicity differ neo-adjuvant/ adjuvant chemotherapy regimen . - To assess correlation CIA depletion ovarian follicular reserve . - To partly externally validate precede study anti-mullerian hormone level patient receive neo-adjuvant/ adjuvant chemotherapy breast cancer . - To determine efficacy GNRH agonists preservation ovarian follicle premenopausal woman treat adjuvant neo-adjuvant chemotherapy breast cancer . Administration GNRH agonists dependent treat oncologist 's judgment patient 's case practice influence study participation .</brief_summary>
	<brief_title>Anti-Mullerian Hormone Study . ICORG 10-16 , V2</brief_title>
	<detailed_description>Type Study : Translational Study Sample Type : A 10mL blood sample collect red vacutainer tube ( anticoagulant , gel ) patient designate time point +/- 7days . Blood preferably collect follicular phase menstrual cycle . Time Sample procurement : - 1st Sample : Pre-Chemotherapy ( â‰¤ 14 day pre-treatment ) - 2nd Sample : e.g . cycle 3 , undergo 4 cycle regimen cycle 4 6 cycle regimen . ( If chemotherapy regimen change follow commencement chemotherapy &amp; /or surgery , blood sample take time point determine original plan i.e . patient 6 cycle chemotherapy change 4 cycle sample take cycle 4 ) - 3rd sample : 3 week follow last dose chemotherapy - 4th sample : 3 month follow last dose chemotherapy - 5th sample : 6 month follow last dose chemotherapy - 6th sample : 1 year follow last dose chemotherapy - 7th sample : 2 year follow last dose chemotherapy - 8th sample : 3 year follow last dose chemotherapy Patient 's menstrual status include commencement date last menstrual period use Intra Uterine Devices ( IUD ) FSH , LH E2 level document Baseline Assessment CRF . FSH , LH E2 level also measure time point document Follow-up Assessment CRF .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<criteria>1 . Documented histological diagnosis invasive breast cancer 2 . Patient due treat chemotherapy ( neoadjuvant adjuvant ) [ Patients treat GNRH agonist adjuvant Herceptin participate clinical trial also eligible ] 3 . Female patient age 18 42 year 4 . Premenopausal status define hormone profile ( FSH , LH , E2 within premenopausal range define local lab ) . OR The last menstrual period within 180 day OR An IUD use contraception 5 . Karnofsky score great equal 70 6 . Ability provide write informed consent 1 . Patients hypothalamic/pituitary disorder 2 . History ovarian tumour 3 . Current pregnancy ( pregnancy test per hospital standard prior treatment )</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>42 Years</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>